激素不同吸入方法对过敏性鼻炎-哮喘综合症患者临床症状及生存质量的影响

Effect of treatment on combined allergic rhinitis and asthma syndrome by different ways of inhaling corticosteroids

目的探讨激素不同吸入方法对CARAS患者临床症状及生存质量的影响。方法 90例CARAS患者被随机分为鼻吸组、口吸组及联合组,分别于治疗前后统计患者鼻炎症状积分,ACT、QOL评分及肺功能指标。结果鼻吸组和联合组治疗后鼻炎症状评分明显减少(P<0.05),口吸组也有减少,但无统计学意义(P>0.05)。口吸组、联合组比鼻吸组治疗后ACT、QOL评分及肺功能指标明显提高,且联合组在ACT、QOL评分优于口吸组(P<0.05)。结论口鼻联合吸入激素是控制CARAS患者鼻炎症状、提高哮喘控制水平、改善生存质量的最好方法。

Objective To observe the clinical effect of treatment of combined allergic rhinitis and asthma syndrome （CARAS） by different ways of inhaling corticosteroids. Methods Totally 90 cases of patients suffered from combined allergic rhinitis and asthma syndrome were randomly divided into three groups. Nasal spray group： 30 cases were treated with fluticasones propionate nasal spray 100 μg （2 puffs） a.m. and 150 tLg（3 puffs） p.m. into each nostril twice daily. Inhaling group： 30 cases were treated with fluticasones propionate inhaling 250 μg（2 puffs） twice daily. Combined group： 30 cases were treated with flutieasones propionate nasal spay-inhaling combined administration for 12 weeks, respectively. The symptom scores of rhinitis, asthma, quality of life and pulmonary function were examined before and after treatment. Results The symptom scores of rhinitis after the treatment in the nasal spay groups and the nasal spayinhaling combined groups were significant decreases （ P 〈 0.05 ） , and the inhaling groups showed no significant decreases （ P 〉 0. 05 ）. The scores of ACT, QOL and pulmonary function in the three groups were significant improvement （ P 〈 0. 05 ） compared with nasal spay groups. The inhaling groups and nasal spay-inhaling combined groups, had significant increases （ P 〈 0. 05 ）. The pulmonary function except ACT and QOL was not significant improvement in the nasal spay-inhaling combined groups compared with inhaling groups. Conclusions It is best of all ways that nasal spay-inhaling combined fluticasones propionate can control symptom of rhinitis, and improve control asthma level and quality of life on CARAS.